Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment

Int J Pharm. 2024 Jul 20:660:124309. doi: 10.1016/j.ijpharm.2024.124309. Epub 2024 Jun 6.

Abstract

Delivering novel antimycobacterial agents through the pulmonary route using nanoparticle-based systems shows promise for treating diseases like tuberculosis. However, creating dry powder inhaler (DPI) with suitable aerodynamic characteristics while preserving nanostructure integrity and maintaining bioactivity until the active ingredient travels deeply into the lungs is a difficult challenge. We developed DPI formulations containing levofloxacin-loaded solid lipid nanoparticles (SLNs) via spray-drying technique with tailored aerosolization characteristics for effective inhalation therapy. A range of biophysical techniques, including transmission electron microscopy, confocal microscopy, and scanning electron microscopy were used to measure the morphologies and sizes of the spray-dried microparticles that explored both the geometric and aerodynamic properties. Spray drying substantially reduced the particle sizes of the SLNs while preserving their nanostructural integrity and enhancing aerosol dispersion with efficient mucus penetration. Despite a slower uptake rate compared to plain SLNs, the polyethylene glycol modified formulations exhibited enhanced cellular uptake in both A549 and NR8383 cell lines. The percent viability of Mycobacterium bovis had dropped to nearly 0 % by day 5 for both types of SLNs. Interestingly, the levofloxacin-loaded SLNs demonstrated a lower minimum bactericidal concentration (0.25 µg/mL) compared with pure levofloxacin (1 µg/mL), which indicated the formulations have potential as effective treatments for tuberculosis.

Keywords: Cellular uptake; Dry powder inhaler; Solid lipid nanoparticles.

MeSH terms

  • A549 Cells
  • Administration, Inhalation
  • Aerosols
  • Animals
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology
  • Antitubercular Agents* / administration & dosage
  • Antitubercular Agents* / chemistry
  • Antitubercular Agents* / pharmacokinetics
  • Antitubercular Agents* / pharmacology
  • Cell Line
  • Drug Carriers / chemistry
  • Dry Powder Inhalers*
  • Humans
  • Levofloxacin* / administration & dosage
  • Levofloxacin* / chemistry
  • Levofloxacin* / pharmacology
  • Lipids / chemistry
  • Liposomes
  • Microbial Sensitivity Tests
  • Mycobacterium bovis / drug effects
  • Nanoparticles* / chemistry
  • Particle Size*
  • Polyethylene Glycols / chemistry
  • Spray Drying
  • Tuberculosis* / drug therapy

Substances

  • Levofloxacin
  • Antitubercular Agents
  • Lipids
  • Aerosols
  • Lipid Nanoparticles
  • Drug Carriers
  • Polyethylene Glycols
  • Anti-Bacterial Agents
  • Liposomes